Celgene handed over $101 million in upfront monies to San Diego-based Vividion Therapeutics, Inc. as part of an agreement to develop small molecule therapies. Source: BioSpace

In its IPO announcement last week Unum revealed early data from its Phase I non-Hodgkin lymphoma therapy that included toxicity concerns at higher dosing levels. Source: BioSpace

Shares of Prometic Life Sciences Inc. jumped this morning after securing the U.S. Food and Drug Administration’s Rare Pediatric Disease Designation. Source: BioSpace

Vanda Pharmaceuticals announced positive results from its JET8 Phase III clinical trial of Hetlioz for jet lag disorder. Source: BioSpace

Dermira plans to shutter the program and move on to more promising compounds. Source: BioSpace

A mid-stage program aimed at treating myelosuppression in lung cancer patients undergoing chemotherapy is yielding positive results. Source: BioSpace

The U.S. Food and Drug Administration (FDA) issued new draft guidance for preclinical trials in Alzheimer’s. Source: BioSpace

Late Thursday the companies touted biomarker data from an early-stage study that showed the drug lowered the disease-causing protein in people with the disease. Source: BioSpace

Biogen and AbbVie have voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns. Source: BioSpace

A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe. Source: BioSpace